Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1994 4
1996 3
1997 2
1998 4
1999 2
2002 1
2003 1
2004 4
2005 2
2007 1
2008 2
2009 5
2010 1
2011 3
2012 3
2013 3
2014 3
2015 2
2016 3
2017 3
2018 3
2019 6
2020 6
2021 5
2022 7
2023 12
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Protein epitope mimetic macrocycles as biopharmaceuticals.
Luther A, Moehle K, Chevalier E, Dale G, Obrecht D. Luther A, et al. Among authors: chevalier e. Curr Opin Chem Biol. 2017 Jun;38:45-51. doi: 10.1016/j.cbpa.2017.02.004. Epub 2017 Apr 20. Curr Opin Chem Biol. 2017. PMID: 28319811 Review.
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.
Audrain M, Egesipe AL, Tentillier N, Font L, Ratnam M, Mottier L, Clavel M, Le Roux-Bourdieu M, Fenyi A, Ollier R, Chevalier E, Guilhot F, Fuchs A, Piorkowska K, Carlyle B, Arnold SE, Berry JD, Luthi-Carter R, Adolfsson O, Pfeifer A, Kosco-Vilbois M, Seredenina T, Afroz T. Audrain M, et al. Among authors: chevalier e. Brain Commun. 2023 Nov 3;5(6):fcad306. doi: 10.1093/braincomms/fcad306. eCollection 2023. Brain Commun. 2023. PMID: 38025276 Free PMC article.
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.
Afroz T, Chevalier E, Audrain M, Dumayne C, Ziehm T, Moser R, Egesipe AL, Mottier L, Ratnam M, Neumann M, Havas D, Ollier R, Piorkowska K, Chauhan M, Silva AB, Thapa S, Stöhr J, Bavdek A, Eligert V, Adolfsson O, Nelson PT, Porta S, Lee VM, Pfeifer A, Kosco-Vilbois M, Seredenina T. Afroz T, et al. Among authors: chevalier e. Neurobiol Dis. 2023 Apr;179:106050. doi: 10.1016/j.nbd.2023.106050. Epub 2023 Feb 20. Neurobiol Dis. 2023. PMID: 36809847 Free article.
Chemokine receptors as targets for cancer therapy.
Wu X, Lee VC, Chevalier E, Hwang ST. Wu X, et al. Among authors: chevalier e. Curr Pharm Des. 2009;15(7):742-57. doi: 10.2174/138161209787582165. Curr Pharm Des. 2009. PMID: 19275640 Review.
Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist.
Dickson L, Teall M, Chevalier E, Cheung T, Liwicki GM, Mack S, Stephenson A, White K, Fosbeary R, Harrison DC, Brice NL, Doyle K, Ciccocioppo R, Wu C, Almond S, Patel TR, Mitchell P, Barnes M, Ayscough AP, Dawson LA, Carlton M, Bürli RW. Dickson L, et al. Among authors: chevalier e. ACS Med Chem Lett. 2023 Mar 2;14(4):442-449. doi: 10.1021/acsmedchemlett.2c00529. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077399 Free PMC article.
88 results